Recombinant botulinum toxin (biosynthetic Botox)

01Overview and value chain

Markers: [EC: FDA Biologics License Application (BLA) / EU Centralised Procedure (CHMP→EC) / NMPA Biological Products Approval | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) replace the traditional Clostridium botulinum batch fermentation — a high-containment, low-yield process tied to the 900 kDa toxin complex — with biosynthetic production (recombinant serotype expression in microbial or cell-free systems) or downstream engineering that strips the complexing proteins to deliver a “naked” 150 kDa neurotoxin. The global botulinum toxin market exceeded $7 billion in 2026, with AbbVie’s Botox franchise commanding approximately 60% of US neuromodulator share. Three differentiated product profiles launched or won approval in 2026: AbbVie/Allergan’s Boey® (trenibotulinumtoxinE) — the first recombinant botulinum neurotoxin serotype E approved for aesthetic use, with onset as early as 8 hours and effects lasting 2-3 weeks across 2,100+ Phase 3 patients; Galderma’s Relfydess™ (relabotulinumtoxinA) — the first ready-to-use liquid neuromodulator manufactured with PEARL™ Technology, complex-free BoNT-A1 with onset as early as Day 1 and 6-month sustained effect in roughly 75% of patients across 1,900+ READY trial participants; and Eirion Therapeutics’ AI-09 — a ready-to-use liquid injectable recombinant BoNT-A that achieved a median 26-week (6-month) duration at the highest dose in a 96-subject Phase 1-2 trial. Merz’s Xeomin (incobotulinumtoxinA, approved in 79 countries) pioneered the complexing-protein-free “naked toxin” profile. The serotype E Boey approval (Health Canada June 2026, EU July 2026, FDA Complete Response Letter April 2026 citing manufacturing only) marks the first new botulinum neurotoxin serotype approved for aesthetic use since the original BoNT-A products.

The key directions of recombinant botulinum toxin are:

1. Recombinant serotype-E neurotoxin (TrenibotulinumtoxinE / Boey): AbbVie/Allergan’s first-in-class recombinant BoNT/E targeting SNAP-25, with onset as early as 8 hours and 2-3 week duration, approved in Canada (June 23, 2026) and across the 30 EEA countries (July 17, 2026) following a positive CHMP opinion (May 21, 2026); US BLA under Complete Response Letter (April 23, 2026) for manufacturing only, no additional clinical studies requested.
2. Ready-to-use liquid neuromodulators (PEARL Technology): Galderma’s Relfydess™ (relabotulinumtoxinA, formerly QM1114) — first ready-to-use liquid neuromodulator manufactured via Precipitation-free Extraction and Activity-preserving, Refined Liquid (PEARL™) Technology from a proprietary C. botulinum A1 strain, producing a complex-free BoNT-A1 molecule with day-1 onset and 6-month sustained effect; 33 markets approved, 20+ launched.
3. Complexing-protein-free naked toxin (Xeomin): Merz Therapeutics’ incobotulinumtoxinA — BoNT-A manufactured with proprietary purification technology that removes accessory complexing proteins during production, yielding the 150 kDa neurotoxin alone; approved in 79 countries, with Japan MHLW cervical-dystonia/blepharospasm approval (June 19, 2026) and EU pediatric spasticity submission (January 26, 2026) on Phase 3 ELLIE data.
4. Recombinant liquid injectable & topical neuromodulators (AI-09 / ET-01): Eirion Therapeutics’ AI-09 ready-to-use liquid injectable BoNT-A achieved 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial and entered Phase 2 (NCT07321834) in December 2025; ET-01 topical BoNT in Phase 2; backed by a $40M Haohai Biological Technology licensing deal and HTL Biotechnology (France) manufacturing.

Sectoral value chain

[recombinant gene construct / proprietary C. botulinum A1 strain] ──> [upstream fermentation / cell culture]
                                                                                              │
                                                                              (150 kDa neurotoxin)
                                                                                              │
                                                                                              ▼
[ready-to-use liquid or lyophilized vial] <─── [fill-finish & QC] <─── [complexing-protein removal / PEARL formulation] <─── [chromatographic purification]

Value chain levels

Cross-cutting technologies of the sector:

• PEARL™ Technology ready-to-use liquid formulation (PEARL Technology Ready-to-Use Liquid BoNT-A): Galderma’s Precipitation-free Extraction and Activity-preserving, Refined Liquid process delivers relabotulinumtoxinA as a stable complex-free liquid that requires no reconstitution, with a measured 0.27 ng BoNT-A1 per glabellar-line dose and 53 BoTest® activity units versus onabotulinumtoxinA’s 0.18 ng and 29 units.
• Complexing-protein-free naked toxin purification (Complexing-Protein-Free Naked Toxin Purification): Merz’s proprietary purification technology strips the 750 kDa neurotoxin-associated proteins during manufacturing, leaving only the 150 kDa active neurotoxin (incobotulinumtoxinA) — claimed to reduce immunogenicity risk over long treatment cycles.
• Ready-to-use recombinant liquid injectable (Ready-to-Use Recombinant Liquid Injectable Neuromodulator): Eirion’s AI-09 formulated as a ready-to-use liquid injectable BoNT-A, achieving a 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial and entering Phase 2 (NCT07321834) in December 2025.

02US

The US hosts the only approved recombinant botulinum neurotoxin serotype E program (AbbVie/Allergan’s Bonti-origin Boey pipeline) and the leading clinical-stage recombinant liquid-injectable developer (Eirion Therapeutics), with the FDA’s Biologics License Application pathway governing every new molecular entity.

Bonti-origin recombinant serotype E, Eirion ready-to-use liquid, FDA BLA pathway

• AbbVie / Allergan Aesthetics (Boey® / trenibotulinumtoxinE, recombinant serotype E): the first and only botulinum neurotoxin serotype E to receive aesthetic approval — Health Canada approval June 23, 2026 (first country to approve a new botulinum neurotoxin serotype for aesthetic use), positive CHMP opinion May 21, 2026 (30 EEA markets), and European Commission approval July 17, 2026; the US BLA (submitted April 24, 2025) received a Complete Response Letter on April 23, 2026 citing manufacturing process observations only — no safety/efficacy concerns, no additional clinical studies requested — supported by 2,100+ patients across pivotal Phase 3 trials (M21-500, M21-508) with onset as early as 8 hours and 2-3 week duration; North Chicago, Ill. headquarters.
• Eirion Therapeutics (AI-09 / ET-01 recombinant neuromodulator pipeline, Woburn MA): AI-09 — a ready-to-use liquid injectable recombinant BoNT-A — achieved clinically and statistically significant results with a 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial (October 2024, four US investigational sites), entered Phase 2 (NCT07321834) in December 2025; ET-01 topical BoNT in Phase 2; backed by a $40 million investment/licensing deal with Shanghai Haohai Biological Technology and a manufacturing deal with HTL Biotechnology (France).
• FDA BLA regulatory framework: both recombinant serotype E (trenibotulinumtoxinE) and new ready-to-use liquid formulations (relabotulinumtoxinA) clear the US market via the Biologics License Application pathway under 351(a) of the Public Health Service Act, with the FDA’s April/July 2026 Complete Response Letters to AbbVie and Galderma both citing manufacturing-site observations only and explicitly identifying no safety or efficacy deficiencies — a signal that the next-generation BoNT field’s regulatory bottleneck is CMC (Chemistry, Manufacturing and Controls) rather than clinical.

03CN

China’s botulinum toxin market is dominated by Lanzhou Institute of Biological Products’ Hengli® (衡力) — the country’s first domestic BoNT-A, derived from C. botulinum A fermentation since 1993 with a 2002 NMPA approval — while genuinely recombinant Chinese BoNT R&D remains pre-commercial, concentrated in academic and clinical-stage biotech pipelines.

Lanzhou Hengli dominance, post-Botox domestic displacement, recombinant R&D frontier

• Lanzhou Institute of Biological Products / CNBG (衡力® Hengli): a subsidiary of China National Biotec Group (国药集团中国生物), the 30+ year national BoNT incumbent with 5,000+ medical institutions nationwide; 2025-2026 first-in-China indication expansions — primary axillary hyperhidrosis (NMPA approval November 25, 2025) and benign masseter hypertrophy (NMPA approval April 27, 2026, Phase 3 by Li Qingfeng at Shanghai Jiao Tong University’s 9th People’s Hospital across 16 centers); pricing 1,200-2,500 RMB/100U, 3-4 month duration; still traditional fermentation, not recombinant.
• Domestic displacement and recombinant R&D pipeline: a 2025 China industry ranking (AskCI) names Hengli as the domestic market leader on cost and grassroots penetration, with Allergan Botox and Galderma Dysport leading imports; the same ranking names 圣湘生物 (Sansure Biotech) as exploring recombinant BoNT via gene technology and 诺诚健华 (InnoCare) / 信达生物 (Innovent) targeting therapeutic BoNT via protein engineering — but no Chinese recombinant BoNT product has reached commercial launch as of 2026.
• NMPA regulatory pathway: Chinese botulinum neurotoxin approvals (including Hengli’s 2025-2026 indication expansions) flow through NMPA’s biological products approval process under CNBG’s national-core-technology classification; the lack of a recombinant BoNT product in the Chinese pipeline reflects both the maturity of traditional fermentation economics and the regulatory novelty of recombinant serotype-E / complexing-protein-free architectures in the China market.

04EU

The EU approved two flagship next-generation botulinum neurotoxins in 2026 — AbbVie/Allergan’s recombinant serotype-E Boey® (via Centralised Procedure, July 17, 2026 across all 30 EEA countries) and Galderma’s Relfydess™ relabotulinumtoxinA (via Decentralised Procedure, positive decision July 2026 across 16 concerned countries) — and hosts Merz Pharma’s complexing-protein-free Xeomin (incobotulinumtoxinA) program out of Frankfurt.

AbbVie Boey serotype E, Galderma Relfydess PEARL, Merz Xeomin naked toxin

• AbbVie / Allergan Aesthetics (Boey® / trenibotulinumtoxinE, recombinant serotype E): positive CHMP opinion May 21, 2026 followed by European Commission approval July 17, 2026 — the centralized procedure decision applies across all 30 EEA countries — for the temporary improvement of moderate-to-severe glabellar lines, supported by two pivotal Phase 3 trials demonstrating onset as early as 8 hours and 2-3 week duration; first and only botulinum neurotoxin serotype E approved in Europe.
• Galderma (Relfydess™ / relabotulinumtoxinA, formerly QM1114, Zug Switzerland): completed the EU Decentralised Procedure with a positive decision in July 2026 across 16 concerned countries — the first neuromodulator in Europe to receive simultaneous approval for two indications (glabellar lines + lateral canthal lines); manufactured with PEARL™ Technology from a proprietary C. botulinum type A1 strain as a complex-free ready-to-use liquid; Phase III READY trial of 1,900+ participants showed day-1 onset in up to 39% of patients and 6-month sustained improvement in roughly 75%; approved in 33 markets, launched in 20+ (Europe, UK, Middle East, Asia, Australia).
• Merz Therapeutics (XEOMIN® / incobotulinumtoxinA, Frankfurt am Main Germany): the complexing-protein-free “naked toxin” BoNT-A, manufactured via Merz’s proprietary purification technology that removes accessory proteins during production; approved in 79 countries for therapeutic and aesthetic indications, with EU EMA submission (January 26, 2026) for pediatric spasticity (ages 2-17) on Phase 3 ELLIE data, and an expanded Grünenthal partnership into Brazil effective July 1, 2026.

05Leading companies and research institutes

06Tech stack and innovations

The recombinant and next-generation BoNT stack rests on three engineering layers — serotype / molecule selection, complexing-protein downstream processing, and ready-to-use liquid formulation — each of which can differentiate a product on onset speed, duration, or immunogenicity profile.

1. Recombinant serotype-E expression (Recombinant BoNT Serotype E Expression):
   • AbbVie/Allergan’s Boey (trenibotulinumtoxinE) expresses BoNT serotype E (rather than the dominant serotype A of all prior aesthetic products), targeting SNAP-25 at a different cleavage site than BoNT/A and delivering a rapid-onset (8 hours), short-duration (2-3 weeks) profile aimed at neurotoxin-naive patients.
   • The Bonti-origin program is the first new botulinum neurotoxin serotype approved for aesthetic use since the original BoNT-A wave of the 1990s-2000s; supported by 2,100+ patients across the pivotal Phase 3 M21-500 and M21-508 trials plus an open-label safety study.
2. PEARL™ Technology complex-free liquid formulation (PEARL Technology Ready-to-Use Liquid BoNT-A):
   • Galderma’s Precipitation-free Extraction and Activity-preserving, Refined Liquid process produces relabotulinumtoxinA as a complex-free BoNT-A1 liquid from a proprietary C. botulinum A1 strain; the PubMed-characterized output delivers 0.27 ng BoNT-A1 per glabellar-line dose and 53 BoTest® units of specific enzyme activity, versus onabotulinumtoxinA’s 0.18 ng and 29 units — yielding earlier SNAP-25 cleavage and the day-1 onset seen in the 1,900+ patient READY trial.
   • Eliminates reconstitution entirely (the powder-to-liquid step required for Botox, Xeomin and Boey), enabling volumetric dosing and a longer shelf life as a stable liquid.
3. Complexing-protein-free naked toxin purification (Complexing-Protein-Free Naked Toxin Purification):
   • Merz’s proprietary purification technology removes the 750 kDa of neurotoxin-associated (complexing) proteins during manufacturing, leaving only the 150 kDa active incobotulinumtoxinA molecule — claimed to reduce immunogenicity risk over the long, repeated injection cycles typical of neurology (spasticity, cervical dystonia) and chronic migraine use.
   • Xeomin’s 79-country approval footprint (including Japan MHLW’s 4th and 5th indication authorizations for cervical dystonia and blepharospasm in June 2026) and the EU pediatric spasticity ELLIE Phase 3 submission (January 26, 2026) establish the complex-free architecture as a validated alternative to the full 900 kDa complex.

07Value chains and production pipelines

Industrial pipeline of recombinant & next-generation botulinum toxin (FDA BLA / EU Centralised Procedure / NMPA biological products)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Strain & construct     │ ───> │ 2. Upstream fermentation  │
│    (recombinant BoNT/E    │      │    (high-containment      │
│    or C. botulinum A1)    │      │    biosafety)             │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chromatographic        │ <─── │ 3. Cell disruption &      │
│    purification           │      │    proteolytic activation  │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Complexing-protein     │ ───> │ 6. Fill-finish & QC       │
│    engineering (PEARL /   │      │    (ready-to-use liquid   │
│    naked toxin)           │      │    or lyophilized vial)   │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Strain & construct

A recombinant BoNT/E gene construct (AbbVie/Allergan Bonti-origin lineage for Boey/trenibotulinumtoxinE) or a proprietary Clostridium botulinum type A1 strain (Galderma’s PEARL feedstock for relabotulinumtoxinA, or Lanzhou/CNBG’s traditional fermentation strain for Hengli) is established as a master / working cell bank under GMP.

Stage 2: Upstream fermentation

High-containment biosafety fermentation (the entire category remains under national core-technology classification in jurisdictions like Korea and China — Hugel’s Geodu factory restricts access to 18 certified employees under National Intelligence Service monitoring) proliferates the bacterial biomass; AbbVie’s Botox franchise and Lanzhou Hengli both operate traditional C. botulinum batch fermentation, while recombinant expression routes (Eirion’s AI-09 via HTL Biotechnology in France) use engineered microbial hosts.

Stage 3: Cell disruption & proteolytic activation

Cell lysis releases the protoxin; an endogenous or added protease nicks the single-chain protoxin into the active di-chain 150 kDa neurotoxin — a heavy chain (cell-binding / translocation domain) and a light chain (zinc-endopeptidase catalytic domain) linked by a disulfide bond — which then cleaves its SNARE target (SNAP-25 for BoNT/A and BoNT/E, VAMP/synaptobrevin for BoNT/B and BoNT/D, syntaxin for BoNT/C).

Stage 4: Chromatographic purification

Affinity and ion-exchange chromatography isolate the 150 kDa neurotoxin from the surrounding 750 kDa of neurotoxin-associated (complexing) proteins and other cellular impurities; Galderma’s PEARL™ Technology uses Precipitation-free Extraction to preserve high specific activity (1.9-2.2 × 10^8 LD50 mouse potency units per mg of BoNT-A1 across four sampled fractions), while Merz’s Xeomin process goes further to strip the complexing proteins entirely.

Stage 5: Complexing-protein engineering

Proprietary downstream processing differentiates the product: Galderma’s PEARL keeps a complex-free BoNT-A1 in stable liquid form, Merz’s Xeomin removes complexing proteins to deliver the naked 150 kDa incobotulinumtoxinA, AbbVie’s Boey carries the recombinant serotype-E molecule in a lyophilized powder for reconstitution, and Eirion’s AI-09 is formulated directly as a ready-to-use liquid injectable.

Stage 6: Fill-finish & QC

Aseptic vial filling yields the finished BoNT product as either a ready-to-use liquid (Galderma Relfydess, Eirion AI-09) or a lyophilized powder requiring reconstitution with saline before injection (AbbVie Botox and Boey, Merz Xeomin); vial formats span 100U / 200U / 300U; lot release requires mouse bioassay potency confirmation and sterility testing under FDA / EMA / NMPA CMC requirements — the same Chemistry, Manufacturing and Controls bottleneck that drove the 2026 FDA Complete Response Letters to AbbVie (Boey, April 23) and Galderma (Relfydess, July 1).